Keyword: AbbVie

With Bristol kicking off 2019 at the dealmaking table, will other companies follow suit? Drugmakers such as AbbVie, Gilead have the need—and the funds.

Could Pfizer's Xeljanz become the 2019 challenger to AbbVie’s Humira TV ad crown?

TV spending on pharma ads continued to rise in 2018, topping $3.73 billion in national TV ad spending, according to data from TV ad tracker iSpot.tv.

Allegations in nearly a dozen kickbacks lawsuits against top pharma companies are unfounded, the government said.

The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.

What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis.

Effective immediately, AbbVie is streamlining its executive team to four managers who will serve under CEO Richard Gonzalez.

Joining the list of top 10 pharma TV spenders were a group of new brands including Aimovig, Mavyret and Truvada.

​​​​​​​AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret that emphasize a cure “in only 8 weeks.”

Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.